NasdaqGM - Nasdaq Real Time Price • USD
Structure Therapeutics Inc. (GPCR)
As of 3:55 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -0.22 | -0.23 | -0.88 | -1.01 |
| Low Estimate | -0.24 | -0.25 | -0.95 | -1.49 |
| High Estimate | -0.2 | -0.21 | -0.76 | 0.35 |
| Year Ago EPS | -0.6 | -0.62 | -2.43 | -0.88 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 8 | 8 |
| Avg. Estimate | -- | -- | -- | 25M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 200M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.28 | -0.29 | -0.21 | -0.21 |
| EPS Actual | -0.6 | -0.62 | -0.66 | -0.19 |
| Difference | -0.32 | -0.33 | -0.45 | 0.02 |
| Surprise % | -114.30% | -113.80% | -214.30% | 9.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.22 | -0.23 | -0.88 | -1.01 |
| 7 Days Ago | -0.22 | -0.23 | -0.88 | -1.01 |
| 30 Days Ago | -0.22 | -0.23 | -0.95 | -0.97 |
| 60 Days Ago | -0.22 | -0.23 | -0.94 | -0.94 |
| 90 Days Ago | -0.24 | -0.27 | -0.99 | -0.67 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 2 | 5 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GPCR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 63.30% | -- | -- | 7.90% |
| Next Qtr. | 62.90% | -- | -- | 10.20% |
| Current Year | 63.80% | -- | -- | 4.80% |
| Next Year | -14.80% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -- | -- | -- | 11.27% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | JP Morgan: Overweight | 5/21/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 5/10/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 5/3/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/18/2024 |
| Initiated | Cantor Fitzgerald: Overweight | 4/9/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 3/8/2024 |
Related Tickers
ALT Altimmune, Inc.
6.98
-4.84%
VKTX Viking Therapeutics, Inc.
65.35
+4.14%
MDGL Madrigal Pharmaceuticals, Inc.
223.14
-2.81%
SRRK Scholar Rock Holding Corporation
10.30
-3.47%
CYTK Cytokinetics, Incorporated
48.09
-0.43%
CRNX Crinetics Pharmaceuticals, Inc.
46.77
-1.47%
ZEAL.CO Zealand Pharma A/S
614.50
-0.41%
TERN Terns Pharmaceuticals, Inc.
6.34
+5.67%
BCYC Bicycle Therapeutics plc
23.03
-0.02%
IMCR Immunocore Holdings plc
46.33
+0.61%